OPDP (Office of Prescription Drug Promotion)
The FDA office that reviews prescription drug promotional materials for compliance.
OPDP, the Office of Prescription Drug Promotion, is the part of the FDA responsible for reviewing prescription drug promotional material, both the ads patients see and the materials aimed at prescribers, for compliance with federal advertising and labeling rules. It was formerly called the Division of Drug Marketing, Advertising, and Communications (DDMAC). The name changed, the job didn't.
OPDP doesn't pre-approve every piece before it runs. Most promotional review happens inside the company, through MLR and a Promotional Review Committee, with OPDP seeing material only once it's filed via Form 2253 or flagged through its own surveillance work, including the Bad Ad program that lets HCPs report concerns directly. When OPDP does find a problem, typically an unsubstantiated claim, a missing risk disclosure, or an overstated efficacy claim, it responds with an untitled letter or, for more serious violations, a warning letter.